AngioDynamics, Inc. (ANGO) CEO James C. Clemmer Buys 20,000 Shares

AngioDynamics, Inc. (NASDAQ:ANGO) CEO James C. Clemmer bought 20,000 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The stock was purchased at an average cost of $15.64 per share, for a total transaction of $312,800.00. Following the completion of the transaction, the chief executive officer now directly owns 86,683 shares in the company, valued at approximately $1,355,722.12. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

AngioDynamics, Inc. (NASDAQ ANGO) traded up 0.29% on Friday, reaching $17.10. The company’s stock had a trading volume of 459,833 shares. The company has a market capitalization of $625.52 million, a price-to-earnings ratio of 124.82 and a beta of 1.15. The stock has a 50 day moving average price of $16.28 and a 200-day moving average price of $16.18. AngioDynamics, Inc. has a 1-year low of $14.80 and a 1-year high of $18.18.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.03. AngioDynamics had a net margin of 2.00% and a return on equity of 5.19%. The firm had revenue of $86.90 million for the quarter, compared to analysts’ expectations of $90.72 million. During the same period in the prior year, the firm earned $0.19 earnings per share. The company’s quarterly revenue was down 7.0% compared to the same quarter last year. Equities analysts predict that AngioDynamics, Inc. will post $0.67 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “AngioDynamics, Inc. (ANGO) CEO James C. Clemmer Buys 20,000 Shares” was first reported by BNB Daily and is owned by of BNB Daily. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/19/insider-buying-angiodynamics-inc-ango-ceo-acquires-312800-00-in-stock-updated-updated-updated.html.

Hedge funds have recently added to or reduced their stakes in the stock. Comerica Bank boosted its stake in AngioDynamics by 14.6% in the fourth quarter. Comerica Bank now owns 33,243 shares of the medical instruments supplier’s stock valued at $592,000 after buying an additional 4,227 shares during the period. State Street Corp boosted its stake in AngioDynamics by 21.4% in the fourth quarter. State Street Corp now owns 801,613 shares of the medical instruments supplier’s stock valued at $13,518,000 after buying an additional 141,424 shares during the period. FMR LLC boosted its stake in AngioDynamics by 1.8% in the fourth quarter. FMR LLC now owns 1,140,000 shares of the medical instruments supplier’s stock valued at $19,232,000 after buying an additional 20,000 shares during the period. New York State Teachers Retirement System boosted its stake in AngioDynamics by 3.4% in the fourth quarter. New York State Teachers Retirement System now owns 15,086 shares of the medical instruments supplier’s stock valued at $255,000 after buying an additional 500 shares during the period. Finally, Public Sector Pension Investment Board boosted its stake in AngioDynamics by 9.8% in the fourth quarter. Public Sector Pension Investment Board now owns 22,424 shares of the medical instruments supplier’s stock valued at $378,000 after buying an additional 2,000 shares during the period. 89.19% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts recently weighed in on ANGO shares. Barclays PLC cut their target price on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 19th. Canaccord Genuity reaffirmed a “hold” rating and issued a $16.50 target price on shares of AngioDynamics in a research report on Wednesday, May 31st. Zacks Investment Research raised AngioDynamics from a “sell” rating to a “hold” rating in a research report on Monday. Cantor Fitzgerald increased their target price on AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 4th. Finally, BidaskClub lowered AngioDynamics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $18.50.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply